Table 2.

Incidence and risks of all-cause mortality, myocardial infarction, stroke, hospitalisation for heart failure and cancer after propensity score matching

	HBV cohort			Control cohort (reference)			Crude		Adjusted
	No of events	Person-years	Incidence rate*	No. of events	Person-years	Incidence rate*	HR (95% CI)	p Value	HR† (95% CI)	p value
All-cause mortality	6027	2 23 588	26.96	7140	2 02 307	35.29	0.78 (0.76 to 0.81)	<0.001	0.72 (0.70 to 0.75)	<0.001
MACE‡	1098	2 20 605	4.98	1663	1 98 131	8.39	0.59 (0.55 to 0.64)	<0.001	0.58 (0.53 to 0.62)	<0.001
Myocardial infarction	308	2 22 847	1.38	554	2 01 078	2.76	0.50 (0.43 to 0.57)	<0.001	0.49 (0.42 to 0.56)	<0.001
Ischaemic stroke	822	2 21 298	3.71	1171	1 99 259	5.88	0.63 (0.57 to 0.69)	<0.001	0.61 (0.56 to 0.67)	<0.001
Heart failure	249	2 23 050	1.12	405	2 01 494	2.01	0.55 (0.47 to 0.65)	<0.001	0.50 (0.43 to 0.59)	<0.001
HCC	1590	2 20 573	7.21	153	2 02 145	0.76	9.58 (8.12 to 11.31)	<0.001	9.34 (7.91 to 11.03)	<0.001
Acute appendicitis	222	2 22 682	1.00	179	2 01 644	0.89	1.13 (0.93 to 1.37)	0.233	1.13 (0.93 to 1.38)	0.227

*Per 10³ person-years.

†Adjusted for monthly income, urbanisation level, Charlson Comorbidity Index score, dipeptidyl peptidase-4 inhibitor use, metformin use, sulfonylurea use, alpha blocker use, dyslipidaemia, atrial fibrillation, peripheral vascular disease and heart failure.

‡Myocardial infarction and ischaemic stroke.

HBV, hepatitis B virus; HCC, hepatocellular carcinoma; MACE, major adverse cardiovascular event.